The Integrated Genomics Operation (IGO) at Memorial Sloan Kettering Cancer Center provides a comprehensive suite of genomic services aimed at advancing basic, clinical, and translational research. The IGO is equipped with a wide array of genomic platforms, including a full range of Illumina next-generation sequencing (NGS) instruments, which facilitate various sequencing applications. This centralized approach to sequencing activities allows researchers to efficiently evaluate gene expression, chromosome structure, and nucleotide sequences, thereby empowering scientists with flexible and cost-effective options for high-throughput genomics.

In addition to its sequencing capabilities, the IGO supports a robust framework for translational research through its Human Oncology and Pathogenesis Program (HOPP). This program bridges laboratory research and clinical application, focusing on the development of next-generation cancer treatments. HOPP employs innovative technologies to redefine the discovery and testing of new therapies, while also providing training for emerging scientists and physicians. By fostering collaboration between basic science and clinical research, HOPP aims to accelerate the translation of laboratory findings into effective cancer treatments, ultimately enhancing patient care and outcomes.

United States

The Integrated Genomics Operation (IGO) at Memorial Sloan Kettering (MSK) is a collaborative core facility dedicated to generating high-quality genomics data for basic, translational, and clinical research projects. The core is focused on Illumina Next-Generation Sequencing (NGS) while also providing comprehensive genomics services including pathological review of tissue samples, fragment analysis, Sanger sequencing, and much more.

Sloan Kettering Integrated Genomics Operation

Company Details